This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bioniche Engages Evercore Partners To Assist In The Divestment Of Its Animal Health Business

BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore Partners (Evercore) to assist the Board of Directors and management in its divestment of the Animal Health business. Evercore is a leading independent advisory firm in the U.S. that specializes in merger and acquisition transactions, divestitures and restructurings.

This decision to divest the Animal Health business was taken following several months of discussion between the Board of Directors and management related to unlocking corporate value for the benefit of all shareholders, and following the receipt of several unsolicited offers to purchase the business.

"Three large Animal Health companies have now expressed interest, in writing, in executing a purchase of the Company's Animal Health business," said Mr. James Rae, Chairman of the Board of Directors of Bioniche Life Sciences Inc. "Evercore's track record in successfully negotiating such transactions and its extensive network of contacts in the animal health industry make it an ideal firm to lead this exercise."

The Company has successfully built its Animal Health business over 34 years to the point where it is profitable before research and development, with a successful mix of products primarily in livestock reproduction, immunotherapeutics, equine performance, and companion animals. The Bioniche brand of products and its infrastructure have been highly regarded for many years, and the Company is regularly approached by other animal health companies seeking to enhance their own offerings by way of partnership or acquisition of Bioniche assets.

As Evercore leads its work on the Animal Health side of the business, the Company is actively engaged in discussions with potential partners for its Phase III bladder cancer product, Urocidin™, which will unlock value for the Company's Bioniche Therapeutics Corp. subsidiary . Since learning that the Company was regaining the global rights to Urocidin™, more than 30 companies have expressed an interest in marketing the product, and discussions with these companies are at various stages. Such partnership arrangements generally include up-front and milestone payments, as well as financial support for development costs to offset additional clinical trial work that the Company is required to complete for successful commercialization of Urocidin™. In recent weeks, a preliminary equity investment offer and a preliminary licensing offer have been received in relations to Bioniche Therapeutics Corp. and Urocidin™ respectively.

With regard to Bioniche One Health and the Company's Animal Health and Food Safety Vaccine Manufacturing Centre in Belleville, the Company has had preliminary discussions with companies that have an

interest in potential partnerships around Econiche®, the E. coli O157 cattle vaccine and around manufacturing capacity in the Vaccine Manufacturing Centre (VMC).

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs